DNA Repair Biomarkers Predict Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer

被引:45
|
作者
Alexander, Brian M. [1 ]
Wang, Xiao Zhe [2 ,3 ]
Niemierko, Andrzej
Weaver, David T. [2 ,3 ]
Mak, Raymond H.
Roof, Kevin S. [6 ]
Fidias, Panagiotis [4 ]
Wain, John [5 ]
Choi, Noah C.
机构
[1] Harvard Univ, Sch Med, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA
[2] On Q Ity Inc, Waltham, MA USA
[3] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[5] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA
[6] SE Radiat Oncol, Charlotte, NC USA
关键词
Biomarkers; Chemoradiotherapy; DNA repair; Esophageal cancer; SQUAMOUS-CELL CARCINOMA; POOR-PROGNOSIS; CHEMOTHERAPY; EXPRESSION; CHEMORADIATION; DEFICIENCY; CISPLATIN; BENEFITS; HMLH1;
D O I
10.1016/j.ijrobp.2011.05.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The addition of neoadjuvant chemoradiotherapy prior to surgical resection for esophageal cancer has improved clinical outcomes in some trials. Pathologic complete response (pCR) following neoadjuvant therapy is associated with better clinical outcome in these patients, but only 22% to 40% of patients achieve pCR. Because both chemotherapy and radiotherapy act by inducing DNA damage, we analyzed proteins selected from multiple DNA repair pathways, using quantitative immunohistochemistry coupled with a digital pathology platform, as possible biomarkers of treatment response and clinical outcome. Methods and Materials: We identified 79 patients diagnosed with esophageal cancer between October 1994 and September 2002, with biopsy tissue available, who underwent neoadjuvant chemoradiotherapy prior to surgery at the Massachusetts General Hospital and used their archived, formalin-fixed, paraffin-embedded biopsy samples to create tissue microarrays (TMA). TMA sections were stained using antibodies against proteins in various DNA repair pathways including XPF, FANCD2, PAR, MLH1, PARP1, and phosphorylated MAPKAP kinase 2 (pMK2). Stained TMA slides were evaluated using machine-based image analysis, and scoring incorporated both the intensity and the quantity of positive tumor nuclei. Biomarker scores and clinical data were assessed for correlations with clinical outcome. Results: Higher scores for MLH1 (p = 0.018) and lower scores for FANCD2 (p = 0.037) were associated with pathologic response to neoadjuvant chemoradiation on multivariable analysis. Staining of MLH1, PARP1, XPF, and PAR was associated with recurrence-free survival, and staining of PARP1 and FANCD2 was associated with overall survival on multivariable analysis. Conclusions: DNA repair proteins analyzed by immunohistochemistry may be useful as predictive markers for response to neoadjuvant chemoradiotherapy in patients with esophageal cancer. These results are hypothesis generating and need confirmation in an independent data set. (C) 2012 Elsevier Inc.
引用
收藏
页码:164 / 171
页数:8
相关论文
共 50 条
  • [1] DNA Repair Biomarkers Predict Response to Neoadjuvant Chemoradiation in Esophageal Cancer
    Alexander, B. M.
    Wang, X.
    Niemierko, A.
    Roof, K. S.
    Fidias, P. M.
    Mathisen, D. J.
    Weaver, D. T.
    Choi, N. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S91 - S91
  • [2] Novel biomarkers that predict response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
    Hasan, Adria
    Demidova, Elena V.
    Czyzewicz, Philip
    Devarajan, Karthik
    Einarson, Margret B.
    Baldwin, Donald
    Golemis, Erica A.
    Meyer, Joshua E.
    Arora, Sanjeevani
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer
    Duong, Cuong
    Greenawalt, Danielle M.
    Kowalczyk, Adam
    Ciavarella, Marianne L.
    Raskutti, Garvesh
    Murray, William K.
    Phillips, Wayne A.
    Thomas, Robert J. S.
    ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (12) : 3602 - 3609
  • [4] Pretreatment Gene Expression Profiles Can Be Used to Predict Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer
    Cuong Duong
    Danielle M. Greenawalt
    Adam Kowalczyk
    Marianne L. Ciavarella
    Garvesh Raskutti
    William K. Murray
    Wayne A. Phillips
    Robert J. S. Thomas
    Annals of Surgical Oncology, 2007, 14 : 3602 - 3609
  • [5] Impact of Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer
    Soror, T.
    Kho, G.
    Zhao, K.
    Ismail, M.
    Badakhsh, H.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S780 - S781
  • [6] Serum biomarkers of VEGF-A and TGF-β1 predict pathological response and survival of esophageal cancer patients treated with neoadjuvant chemoradiotherapy and esophagectomy
    Cheng, Jason Chia-Hsien
    Chiang, Yun
    Hsu, Feng-Ming
    Tsai, Chiao-Ling
    Hsu, Chih-Hung
    Lee, Jang-Ming
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [7] Circulating Biomarkers for Response Prediction of Rectal Cancer to Neoadjuvant Chemoradiotherapy
    Bedin, Chiara
    Crotti, Sara
    D'Angelo, Edoardo
    D'Aronco, Sara
    Pucciarelli, Salvatore
    Agostini, Marco
    CURRENT MEDICINAL CHEMISTRY, 2020, 27 (25) : 4274 - 4294
  • [8] Novel biomarkers to predict treatment response and prognosis in locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy
    Guan, Bingjie
    Xu, Meifang
    Zheng, Rong
    Guan, Guoxian
    Xu, Benhua
    BMC CANCER, 2023, 23 (01)
  • [9] Novel biomarkers to predict treatment response and prognosis in locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy
    Bingjie Guan
    Meifang Xu
    Rong Zheng
    Guoxian Guan
    Benhua Xu
    BMC Cancer, 23
  • [10] Global dna methylation is altered by neoadjuvant chemoradiotherapy in rectal cancer and may predict response to treatment
    Tsang, J. S.
    Leen, E.
    Kay, E. W.
    Deasy, J.
    McNamara, D. A.
    Mulligan, E. D.
    BRITISH JOURNAL OF SURGERY, 2010, 97 : 34 - 34